Found 29 clinical trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
- 290 views
- 25 Mar, 2021
- 1 location
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA
- 0 views
- 21 Jul, 2022
- 68 locations
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic
- 23 views
- 10 Jul, 2022
- 24 locations
RA-PRO PRAGMATIC TRIAL (RA-PROPR)
medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in
- 0 views
- 28 Jun, 2022
- 1 location
BARIcitinib Cognitive Emotional and Neural signaTuRE (BARICENTRE)
Rheumatoid arthritis (RA) is a frequent and disabling disease, requiring early management to achieve clinical remission. Recently, baricitinib (jak1-jak2 inhibitor) has been shown to as an
- 0 views
- 24 Apr, 2022
- 1 location
Combination of Baricitinib and Adalimumab in Rheumatoid Arthritis (CRI-RA)
patients treated with a combination of MTX and biologic as second-line therapy. Less than 10% of patients treated with a combination of MTX and another targeted DMARD, such as baricitinib, as
- 0 views
- 15 Mar, 2022
- 6 locations
Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus
This research study is evaluating the safety and efficacy of Baricitinib in treating Cutaneous Lichen Planus (LP).
- 0 views
- 22 Mar, 2022
- 1 location
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM (MYOJAK)
This study aims to investigate the clinical efficacy of baricitinib in patients with adult idiopathic inflammatory myositis (IIM). Half of the patients enrolled onto the study will receive 24
- 0 views
- 03 Jun, 2022
- 1 location
Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Treatment of Idiopathic Inflammatory Myopathies
This study aims to explore the clinical characteristics and mechanism research of inhibitors of janus kinase in the treatment of idiopathic inflammatory myopathies
- 0 views
- 14 Jun, 2022
- 1 location
A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to
- 892 views
- 26 Jul, 2022
- 107 locations